The effect of sodium valproate on chronic daily headache and its subgroups

The objective of the study was to assess the efficacy and tolerability of sodium valproate (VPA) on chronic daily headache (CDH) in a prospective, double-blind, randomized, placebo-controlled trial. Seventy patients were included in the study. Twenty-nine had chronic migraine (CM) and 41 had chronic...

Full description

Saved in:
Bibliographic Details
Published in:Journal of headache and pain 2008-02, Vol.9 (1), p.37-41
Main Authors: Yurekli, Vedat Ali, Akhan, Galip, Kutluhan, Suleyman, Uzar, Ertugrul, Koyuncuoglu, Hasan Rifat, Gultekin, Fatih
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Anticonvulsants - administration & dosage
Anticonvulsants - adverse effects
Chronic Disease - drug therapy
Clinical outcomes
Double-Blind Method
Drug therapy
Female
Headache Disorders - classification
Headache Disorders - drug therapy
Headache Disorders - prevention & control
Headaches
Humans
Internal Medicine
Male
Medicine
Medicine & Public Health
Middle Aged
Neurology
Original
Pain Measurement - drug effects
Pain Medicine
Pain Threshold - drug effects
Pain Threshold - physiology
Placebos
Prospective Studies
Sleep Stages - drug effects
Tension-Type Headache - drug therapy
Tension-Type Headache - prevention & control
Treatment Outcome
Valproic Acid - administration & dosage
Valproic Acid - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The objective of the study was to assess the efficacy and tolerability of sodium valproate (VPA) on chronic daily headache (CDH) in a prospective, double-blind, randomized, placebo-controlled trial. Seventy patients were included in the study. Twenty-nine had chronic migraine (CM) and 41 had chronic tension-type headache (CTTH). VPA and placebo were applied for 3 months to 40 and 30 patients, respectively. Visual analog scale (VAS) and pain frequency (PF) were used for evaluation. VPA decreased the maximum pain VAS levels (MaxVAS) and PF at the end of the study ( P  = 0.028 and P  = 0.000, respectively), but did not change general pain VAS (GnVAS) levels ( P  = 0.198). In CM patients, the decreases in MaxVAS, GnVAS and PF parameters were more in VPA treated patients ( P  = 0.006, P  = 0.03, and P  = 0.000, respectively). VPA treatment caused more reduction in PF than placebo in the CTTH subgroup ( P  = 0.000). VPA is effective in the prophylactic treatment of CDH by reducing MaxVAS levels and PF. It was more effective in CM than in CTTH.
ISSN:1129-2369
1129-2377
DOI:10.1007/s10194-008-0002-5